All infants (n = 252) | Group 1 (n = 154) | Group 2 (n = 65) | Group 3 (n = 33) | p Value | |
---|---|---|---|---|---|
*Values are median (range). The units for gestation are completed weeks. | |||||
†Defined as two doses 12 hours apart between 24 hours and 7 days before delivery. | |||||
Group 1, no significant PDA; group 2, significant PDA which closed after medical treatment; group 3, significant PDA remaining patent after medical treatment; PDA, patent ductus arteriosus; SGA, small for gestational age, defined as weight <10th centile for gestational age; CRIB, clinical risk index for babies. | |||||
Gestation* | 26 (22–28) | 27 (23–28) | 25 (22–27) | 24 (22–28) | <0.001 |
Birth weight (g)* | 893 (410–1475) | 998 (470–1475) | 775 (410–1330) | 695 (410–1260) | <0.001 |
SGA | 23 (9%) | 12 (8%) | 7 (11%) | 4 (12%) | 0.638 |
Male sex | 127 (50%) | 79 (51%) | 25 (39%) | 23 (70%) | 0.013 |
Multiple birth | 69 (27%) | 36 (23%) | 20 (31%) | 13 (39%) | <0.001 |
Antenatal steroids | |||||
⩾one dose | 216 (87%) | 135 (88%) | 52 (80%) | 29 (88%) | 0.311 |
Complete† | 101 (47%) | 69 (51%) | 23 (44%) | 9 (31%) | 0.133 |
Any ventilation | 215 (85%) | 118 (77%) | 65 (100%) | 32 (97%) | <0.001 |
CRIB score* | 4 (1–8) | 2 (1–5) | 6 (3–9) | 9 (5–10) | <0.001 |